Biotech firm Cerenis to double space in A2

As Cerenis Theraputics SA moves ahead with its development of a new cholesterol drug, it has expanded its Ann Arbor space from 2,100 to 4,400 square feet.

Excerpt:

[Mary Campbell, general partner and founder of EDF Ventures, an Ann Arbor venture capital firm that has invested in Cerenis, said,]

"There's no such thing as a perfect deal, as they say, but this sure comes awfully close to perfection and I'm thrilled that they are in a position to do some expanding here. It's exactly what Michigan needs.''

The company currently has six employees in Ann Arbor and seven in France.


Enjoy this story? Sign up for free solutions-based reporting in your inbox each week.